SCHEMBL1746513

SCHEMBL1746513

OC/C=C(/c1ccc(Br)cc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.43
PTPN1 P18031 2/20 0.43
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
GPR183 P32249 1/20 0.40
MMP1 P03956 1/20 0.38
SRD5A2 P31213 1/20 0.37
NR4A1 P22736 1/20 0.37
NR4A2 P43354 1/20 0.37
NR4A3 Q92570 1/20 0.37
TRPV1 Q8NER1 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
PPARD Q03181 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746518 1.00 GSK3B (0.43) GSK3BPTPN1CES2CES1GPR183
SCHEMBL1746517 1.00 GSK3B (0.43) GSK3BPTPN1CES2CES1GPR183
SCHEMBL3003288 0.85 PPARD (0.42) GSK3BCES2CES1HDAC1HDAC8
SCHEMBL3946752 0.84 CYP1A1 (0.45) GSK3BPTPN1CES2CES1SRD5A2
SCHEMBL3946748 0.84 CYP1A1 (0.45) GSK3BPTPN1CES2CES1SRD5A2
SCHEMBL1745107 0.83 TRPV1 (0.49) GSK3BPTPN1CES2CES1MMP1
SCHEMBL1745104 0.83 TRPV1 (0.49) GSK3BPTPN1CES2CES1MMP1
SCHEMBL1745106 0.83 TRPV1 (0.49) GSK3BPTPN1CES2CES1MMP1
SCHEMBL1746601 0.80 CTSL (0.42) PTPN1PPARDCYP1A2CYP3A4CYP2D6
SCHEMBL1746419 0.78 CYP3A4 (0.45) PPARDCYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210188758-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS VTVX HOLDINGS II LLC 2021-06-24 US disclosed
US-10947180-B2 Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists VTV THERAPEUTICS LLC (US) 2021-03-16 US disclosed
US-20200215073-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS HIGH POINT PHARMACEUTICALS, LLC 2020-07-09 US disclosed
US-10471066-B2 Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists VTV THERAPEUTICS LLC (US) 2019-11-12 US disclosed
US-20180071304-A1 Phenoxy Acetic Acids and Phenyl Propionic Acids as PPAR Delta Agonists HIGH POINT PHARMACEUTICALS, LLC 2018-03-15 US disclosed
US-9855274-B2 Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists VTV THERAPEUTICS LLC (US) 2018-01-02 US disclosed
US-20170216303-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS HIGH POINT PHARMACEUTICALS, LLC 2017-08-03 US disclosed
US-9663481-B2 Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists VTV THERAPEUTICS LLC (US) 2017-05-30 US disclosed
US-20140024645-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS HIGH POINT PHARMACEUTICALS, LLC (US) 2014-01-23 US disclosed
US-8551993-B2 Phenoxy acetic acids as PPAR delta activators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-10-08 US disclosed
US-20130102610-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2013-04-25 US disclosed
US-8362016-B2 Phenyl propionic acids as PPAR delta activators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-01-29 US disclosed
EP-2386540-A1 Novel compounds, their preparation and use High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
US-20110245244-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2011-10-06 US disclosed
US-7943613-B2 Compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2011-05-17 US disclosed
US-20090093484-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE VTVX HOLDINGS II LLC 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10471066-B2 Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists PPARG, PPARA, PPARD GSK3B 1856/4885PTPN1 2728/4885CES2 1752/4885
US-20090093484-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE PPARG, PPARD, PPARA GSK3B 2133/4885PTPN1 3783/4885CES2 1800/4885
US-20170216303-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS PPARG, PPARA, PPARD GSK3B 1825/4885PTPN1 1215/4885CES2 2044/4885
US-10947180-B2 Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists PPARG, PPARA, PPARD GSK3B 1856/4885PTPN1 2728/4885CES2 1752/4885
US-20180071304-A1 Phenoxy Acetic Acids and Phenyl Propionic Acids as PPAR Delta Agonists PPARG, PPARA, PPARD GSK3B 1856/4885PTPN1 2728/4885CES2 1752/4885
US-20110245244-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS PPARG, PPARA, PPARD GSK3B 1829/4885PTPN1 1838/4885CES2 1515/4885
US-20200215073-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS PPARG, PPARA, PPARD GSK3B 1856/4885PTPN1 2728/4885CES2 1752/4885
US-20130102610-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS PPARG, PPARA, PPARD GSK3B 1829/4885PTPN1 1838/4885CES2 1515/4885
US-20210188758-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS PPARG, PPARA, PPARD GSK3B 1856/4885PTPN1 2728/4885CES2 1752/4885
US-20140024645-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS PPARG, PPARA, PPARD GSK3B 1825/4885PTPN1 1215/4885CES2 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.